Outset Medical, Inc. (NASDAQ:OM) COO Martin Vazquez sold 6,500 shares of the firm’s stock in a transaction dated Friday, September 17th. The shares were sold at an average price of $55.00, for a total transaction of $357,500.00. Following the completion of the sale, the chief operating officer now owns 15,755 shares of the company’s stock, valued at approximately $866,525. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Martin Vazquez also recently made the following trade(s):
- On Wednesday, September 1st, Martin Vazquez sold 5,000 shares of Outset Medical stock. The shares were sold at an average price of $49.17, for a total transaction of $245,850.00.
Outset Medical stock traded down $0.69 during mid-day trading on Monday, hitting $54.29. 688,644 shares of the company were exchanged, compared to its average volume of 478,670. The company has a quick ratio of 11.82, a current ratio of 12.64 and a debt-to-equity ratio of 0.07. The business has a fifty day moving average of $44.42 and a 200 day moving average of $48.30. Outset Medical, Inc. has a 1-year low of $36.03 and a 1-year high of $66.96. The company has a market capitalization of $2.51 billion and a PE ratio of -9.80.
A number of research analysts have weighed in on the stock. Cowen began coverage on shares of Outset Medical in a research report on Wednesday, August 18th. They set an “outperform” rating and a $70.00 price target on the stock. Morgan Stanley lowered their price target on shares of Outset Medical from $60.00 to $55.00 and set an “equal weight” rating for the company in a research report on Monday, August 9th. Finally, Zacks Investment Research downgraded shares of Outset Medical from a “buy” rating to a “hold” rating in a report on Friday. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $59.00.
About Outset Medical
Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.
Featured Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.